Last week, Tara Eacobacci met with his doctor, who was only for the theme of health insurance. The main change in the benefits of her prescription meant that the medicine she used to manage her weight – a treatment that took many years of testing and errors to handle it would no longer be a ban.
“I’m completely outraged,” said Eacobacci. “It not only causes stress, but I am angry.”
Since Tuesday, the CVS CareMark is a major pharmacy benefit manager who is a mediator for health insurers, large employers and other payers to manage their prescription drug plans-2023. November November November November Weight management in adults or adults in adults is governed by adults in adults by adults who are too much.
“This change is happening because there is another coated medicine, safe and effective for your condition and can cost less,” CVS CareMark said in May. In the letter we send to our patients taking Zepbound. “Remember that if you repeated current medicines on February 7, 2012, you will have to pay all the costs.”
Wegovy, GLP-1 medicine to treat obesity from Lilly competitor Novo Nordisk will still apply to plans controlled by CVS Caremark, along with several other medicines that are usually less effective.
CVS says the decision to cover Wegovy and exclude Zepbound is “forcing drug producers to compete with each other” and will encourage both Eli Lilly and Novo Nordisk to reduce their products in the US.
“Important GLP-1S for GLP-1S, due to weight loss, is important for high list prices with the biggest obstacle to patients,” the CVS Health said in a statement. “Our formula strategy supports clinically appropriate coverage and competition to increase lower costs.”
However, the heads of pharmacy benefits, whose CVS Caremark is one of the largest, has been tested for their role as the drug costs increases in the US.
When it comes to weight loss, providers and patients say that GLP-1 medicines are not one swap and that volatile insurance coverage contradicts people who control obesity as a chronic disease, science and experience.
“Most society, we do not accept obesity as long-term chronic diseases and are still looking for quick corrections and quick solutions when it is not the reality of the biology and disease process. The mindset has not yet resisted science,” said Dr. Tracy Zvenyach, Director of Political Strategy and Alliance Obesity Coalition, in the Neproofitrophyte group.
“If decision makers do not realize that obesity is a long -term chronic disease, then when we see this exclusive policy or this very, very complex use of use management, which actually determines one obstacle after another to get people needed.
System of Investigation and Error
It takes time to prepare a treatment plan with GLP-1 medicines that work with each patient, said dr. Jody Dushay, Beth Israel Diakoness Medical Center endocrinologist and assistant to the Harvard Medical School Medical Professor. Some people may have an allergic reaction to the injection site per medicine or have a worse side effect – such as severe constipation, nausea or stomach pain – none.
According to her, adapting to the changes in medication, the patient’s weight loss trajectory is often interrupted, and test and error can cause a lot of waste to medicine that has been missing not too long ago.
“As soon as these messages [about insurance coverage changes] Get out, I was flooded with patients’ reports, “she said.” Very stressed in patients who have been really good, good tolerance and feel that they have struck their step in medicine, nutrition and exercise. Everything goes in the right direction and then can be very destructive. “
When Dushay looks through the patient’s medical chart, she says, her stomach, when she sees a small box indicating their insurance information.
“In this area of weight management, that small part of the diagram dictates so much maintenance of them. For me, it is an unprecedented way to me, how important it is for my clinical care and my choices,” she said.
And discussions on strategies for managing treatment violations in clinical supervision.
“There is little time to ask the patient how he feels about side effects and weight loss and overall health updates,” Dushay said. “Patient care loses time and greatly increases the burden of time not for visiting doctors and pharmacists.”
Another important replacement for next year’s insurance will affect another major fluff of Patients in the Shower: January BCBS Massachusetts will not include all GLP-1 from coverage obesity, reservation only when prescribed type 2 diabetes.
“The nation is facing an obesity crisis. That is why we hardly try to support our members by reaching healthy weight, improving nutritious food, physical activity programs and quality clinical care when needed,” said David Merritt, senior vice president of the Blue Cross Blue Shield Association. “We share enthusiasm for the real weight loss success, which many patients taking GLP-1. Like any new medication, it is necessary to learn to ensure that patients are intended for success. Last year we have announced a study that has found that approximately 60% of people have not been overwhelmed to have a significant weight loss.
Doctors, patients were disappointed
Zepbound and Wegovy are effective in treating obesity and FDA confirms it, but there are differences.
Studies have shown that people who have been taking tirzepatide injections such as Zepbound have lost more weight and are more likely to achieve specific weight loss goals than those taking semaglutido medicines such as Wegovy. Two drugs have a different set of broader indications, and Zepbound also confirmed, for example, to treat sleep apnea, for example, obese people. Side effects may also vary, sometimes to make one medicine tolerated than the other.
People who are lucky with Zepbound can provide an exception after the insurance insurance has changed, but CVS CareMark has limited opportunities to actively plan change, so many patients are angry and concerned about their health and well -being.
Changes and moods of Eacobacci insurance are impressed and based on prejudice.
The CVS CareMark demanded that it test several alternative treatments and prove that they did not work until Zepbound was approved this year. When she was Wegovy, she said her A1C glucose began to grow close to prediabetic levels, despite the consistent diet and exercise habits. All of this changed when she started Zepbound.
“I feel better. I’m not so bloated. My movement is really different. I apply to my clothes, but I also feel confirmed – because all this year, doctors, you say,” Oh, you can’t eat all that pie and candy, “and they don’t believe you don’t,” said Eacobacci. “The medicine actually confirmed some of that.” Hey I need support. I can’t do it on my own as far as I try. “
Pharmaceutical changes can have unnecessarily a dangerous effect on physical health – Eacobacci said she gained 10 pounds and saw her A1C level in just a month without medication, as well as mental health.
“Stigma and bias affected us all over the country,” said Eacobacci, who was worried about many people who she knows who felt depressed after the meeting about the changes in insurance insurance. “You forced me to jump through the bows. I received the previous edition I needed me, and now you-in-wing-in-sees it from me is such an effect that it should be illegal.”
While coverage exceptions may be possible, the appeal process takes time.
“Really, it’s really frustrating that I have to justify what I want to do all the time for money alone,” said Dushay.
For people who lose Zepbound coverage, drug manufacturer Eli Lilly has expanded access through the Lillydirect, a company platform to coordinate remote health services and fill in recipes for patients who pay in the pocket. One dose bottles can be purchased for $ 499 per month per Lillydirect Zepbound Self travel program, and the highest doses can be purchased from July 7th.
“We are convinced that Zepbound’s performance is committed to ensuring that patients have access to the necessary treatment,” Lilly said in a statement.
To get more CNN news and newsletters, create an account on cnn.com